Abstract: A complementary DNA (cDNA) with SEQ ID NO: 1 which encodes an immunogenic fragment of major outer sheath protein (Msp) of Treponema denticola.

Abstract: The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).

Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or anti-body fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of lift of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (oral risk of developing) an elevated serum C-reactive protein level reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

Abstract: The invention provides a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising extracellular domain disclosed herein. Some aspects of the invention relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising the extracellular domain disclosed herein. Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

Abstract: The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.

Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells, e.g., adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for control of therapeutic outcomes. In alternative embodiments, provided are ultrasound-based thermal or mechanical stimulations, and thermo- or mechano-sensitive protein, either synthetically engineered or natively (endogenously) occurring, integrated to control the production of intracellular nucleic acid and gene expression, e.g., for the expression of biological-active proteins, which can be used, in alternative embodiments, for diagnostic or therapeutic purposes.

Abstract: Degradable materials including the reaction product of an oxanorbornadiene crosslinker or derivative thereof and a multivalent nucleophile-terminated compound, wherein the reaction product is a degradable elastic solid capable of entraining cargo. Degradable materials include a polymeric and hyperbranched crosslinked material made with oxanorbornadiene linkage that can be activated for cleavage at a predetermined rate by addition of a nucleophile. Methods of making and using degradable materials are included.

Abstract: Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

Abstract: A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided.

Abstract: The present invention relates to a heart targeting agent comprising tannic acid, in which the agent aids a heart disease therapeutic drug to be delivered to the heart and bind to the cardiac myocardium by inducing tannylation of the drug so as to make heart targeting and accumulation of the drug possible. Unlike the conventional invasive method used for the traditional drugs to be able to target the heart, the agent of the present invention can help a drug to target the heart with high efficiency just via non-invasive intravenous administration.

Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1-H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.

Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.

Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR?3.9 when administered at the same toxin dose.

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

Abstract: The invention provides anti-TPBG antibodies and methods of using the same.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: The present disclosure relates to a light emitting device. The light emitting device includes: a device housing having a structure with an open bottom; and a sterilization module installed in the device housing and emitting ultraviolet light for sterilization. Here, the sterilization module emits the ultraviolet light for sterilization to the open bottom of the device housing.

Abstract: A food ingredient transfer device is provided. The food ingredient transfer device includes a dosing device configured to receive a food ingredient, and a first chamber that is provided with an inlet and an outlet for allowing the dosing device to pass through the first chamber. The food ingredient transfer device further includes a second chamber arranged adjacent to the first chamber for receiving the dosing device when it has passed through the first chamber, the second chamber being provided with an outlet for allowing the dosing device to pass through the second chamber and into an enclosure that contains a food product to which the food ingredient shall be transferred.

Abstract: A sanitizing system for sanitizing a laundry sling that is moveable along one or more support rails includes a motor, a cable operatively coupled to the motor, a sanitizing lamp coupled to the cable, and a controller configured to cause the motor to operate such that the sanitizing lamp is moved, via the cable, from a first position to a second position and actuate the sanitizing lamp such that the sanitizing lamp emits a sanitizing wavelength of light.

Abstract: A decontamination assembly, for pharmaceutical applications includes at least one chamber to be decontaminated (4) having a decontamination liquid storage tank (36) by which several atomizers (A, B, C. D) disposed in the chamber to be decontaminated (4) for producing a decontaminant aerosol can be supplied with decontamination liquid using valves (27) which can be controlled by electronic control, the atomizers (A, B, C, D) being in fluid communication with a ring conduit (32) having an inlet (33) and a separate outlet (34) by the valves (27), decontamination liquid from the decontamination liquid storage tank (36) being conveyable into the inlet of the ring conduit by a pump (35) and decontamination liquid flowing out of the outlet of the ring conduit back into the decontamination liquid storage tank (36), and a pressure adjustment mechanism (37) for keeping the pressure in the ring conduit (32) at a predefined liquid pressure range assigned to the ring conduit (32).

Abstract: A scent dispensing device is provided that includes a plurality of containers, each containing a different scent ingredient; a driving system configured to separately cause each of the plurality of containers to dispense a quantity of the respective scent ingredient; and a delivery system configured to transport any dispensed quantities from the scent containers to a common receiving area for dispensing onto to a single medium.

Abstract: Handheld and rechargeable battery operated device that eliminates the bad odor coming from human flatulence and feces by ignition.

Abstract: An air purifier system includes a duct, an ultraviolet light assembly, and a fan. The duct defines a reaction chamber for the flow of air, and includes an inlet portion and an outlet portion. The ultraviolet light assembly is adapted to illuminate the reaction chamber with ultraviolet light. The fan is adapted to draw the air through the reaction chamber. A reflective surface of the fan is configured to reflect the ultraviolet light into the reaction chamber.

Abstract: Described herein is an absorbent article including (a) an absorbent core, a first nonwoven material, a second nonwoven material, and a bond area; and (b) a polymeric filler composition disposed within the bond area. The polymeric filler composition has less than 1% of a tackifier. The polymeric filler composition is chosen from a propylene butene copolymer, a polypropylene homopolymer, a propylene ethylene copolymer, and mixtures thereof. The polymeric filler composition has a Tensile Strength at Yield of from about 0.5 MPa to about 10 MPa. The bond area has a Peak Peel Strength of from about 0.1 N/cm to about 9 N/cm after exposure to a skin-protecting material for 24 hours.

Abstract: An absorbent article comprising a first nonwoven material joined to a second nonwoven material by at least one bond area, wherein a polymeric filler composition is disposed within the bond area and the composition comprises at least one polymer selected from the group consisting of polypropylene homopolymers, propylene-ethylene copolymers, and mixtures thereof, wherein the composition is substantially free of tackifiers. It was found that such polymer filler compositions having a Toughness of at least 25 MPa, as measured according to the Extensional Test Method described herein, provide bonds with good resistance to peel creep force.

Abstract: Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

Abstract: The present invention relates to protection and communication apparatuses, methods and kits, especially for maintaining position and sealing of protective and/or communication headwear about a head/neck/ear region and in particular in maintaining position and sealing of an ear phone or hearing aid or the like within the acoustic meatus of an ear so as to exclude entry of sonic, sound or vibrational waves to the inner ear and tympanic membrane.

Abstract: A polycaprolactone fumarate polymer useful as a matrix material for a biocompatible scaffold for tissue engineering applications is disclosed. The polycaprolactone fumarate polymer can be prepared by reacting caprolactone with an alkane polyol to prepare a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to prepare the polycaprolactone fumarate polymer. The use of an alkane diol, such as 1,2-propanediol, provides a linear polycaprolactone diol precursor. The use of an alkane triol, such as glycerol, provides a branched polycaprolactone triol precursor. The biocompatible polycaprolactone fumarate formulation releases no diethylene glycol or other undesirable byproducts during degradation.

Abstract: Described herein are gelatin nanoparticles including their use in a composition. The composition may comprise a plurality of gelatin nanoparticles, at least one polymer, and water. In some embodiments, the composition comprises cells. The composition may be in the form of a hydrogel. Methods of using such gelatin nanoparticles and/or compositions are also described.

Abstract: Aspects of the disclosure relate methods and synthetic scaffolds for regenerating hallow organs present in the respiratory system such as bronchus tissue.

Abstract: The present invention comprises a polymer and/or polymer composite based sleeve to be fitted between an extended body, such the neck, trunnion, and/or stem of a hip implant, and a receiving body, such as a femoral head in a hip implant, that reduces wear, decreases toxic material from wear debris, enhances the mechanical connection of the extension and receiving body, reduces or eliminates impingement with receiving body, delocalize stress concentrations, and may also serve as a modifying junction between an extension and receiving body of unmatched size. The polymeric based sleeve presently disclosed comprises an inert and/or biologically favorable material which may be used in its virgin form or contain biocompatible additives. In order to best match patient and implant requirements, modifications may be made in the length, thickness, composition, as well as the presence of a taper, or lack thereof, in order to be compatible with existing devices.

Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.

Abstract: The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Abstract: The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Abstract: The present invention refers to a method for the synthesis of a biodegradable calcium release material that shows controlled ion release properties for tissue engineering, biomaterials containing the calcium particles as well as the calcium particles obtainable therefrom. By varying the treatment temperature of the described method, the calcium material shows different calcium release profiles. Contrary to a specific chemical composition such as CaCO3 which is associated to a specific calcium release profile, the present invention allows a manifold of compositions, with a manifold of calcium release profiles, all starting from a single specific chemical composition calcium precursor. Therefore, the invention also relates to the use of the controllable release, calcium material in tissue regeneration such as wound healing processes.

Abstract: This bone substitute includes a calcium phosphate-type porous ceramic body having spherical voids; and a bioactive glass layer that is formed of a bioactive glass, coats an inner surface of each of the voids and has a thickness of less than 50 ?m. The porous body has communication holes through which the voids communicate with each other.

Abstract: The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 ?m, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 ?m, and having a surface area percentage of micropores in a range of 10-40%.

Abstract: Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

Abstract: A self-expandable stent which has sufficient radial force, good flexural properties, and recovers the shape from a diameter in a contracted state to a diameter before contraction in a short period of time at approximately body temperature (37° C.). The self-expandable stent includes a crosslinked polymer that includes constitutional unit (A), which is a rigid biodegradable polymer derived from a first monomer; constitutional unit (B), which is a rubber-like biodegradable polymer derived from a second monomer; and constitutional unit (C) derived from a crosslinking agent. The constitutional unit (C) is present in an amount that is equal to or greater than 10% by weight and less than 60% by weight based on the total amount of constitutional units (A) and (B).

Abstract: Provided herein relates to implantable devices and systems with dynamic silk coatings. In some embodiments, the dynamic silk coatings can be formed in situ or in vivo.